Abstract
TAFRO (thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly) syndrome is an atypical manifestation of Castleman’s disease. However, the mechanism underlying this very rare syndrome remains unknown, and there is no established standard treatment. Here we report cases of two young females with TAFRO syndrome who showed similar clinical courses. Both cases showed severe anasarca, ascites, and thrombocytopenia. Although high-dose steroids were ineffective, combination chemotherapy showed remarkable effects. However, both patients developed severe but reversible heart failure after CHOP therapy owing to diffuse cardiomyopathy, which was presumably associated with TAFRO syndrome. Therefore, although combination chemotherapy may be very effective in the treatment of TAFRO syndrome, careful observation for cardiomyopathy development is needed, particularly when using adriamycin-containing regimens.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53(1):57–61.
Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91(2):220–6.
Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, et al. Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy—a case report. Exp Hematol Oncol. 2015;4(1):3.
Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, et al. Durable remission with rituximab in a patient with an unusual variant of Castleman’s disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015;90(11):1091–2.
Jouvray M, Terriou L, Meignin V, Bouchindhomme B, Jourdain M, Lambert M, et al. Pseudo-adult Still’s disease, anasarca, thrombotic thrombocytopenic purpura and dysautonomia: an atypical presentation of multicentric Castleman’s disease. Discussion of TAFRO syndrome. Rev Med Interne. 2016;37(1):53–7.
Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, et al. Successful treatment of a patient with multicentric Castleman’s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med. 2013;52(13):1503–7.
Fujiwara S, Mochinaga H, Nakata H, Ohshima K, Matsumoto M, Uchiba M, et al. Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol. doi:10.1007/s12185-016-1978-2
Ozawa T, Kosugi S, Kito M, Onishi M, Kida T, Nakata S, et al. Efficacy of rituximab for TAFRO syndrome, a variant type of multicentric Castleman’s disease. Rinsho Ketsueki. 2014;55(3):350–5.
Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M, Ota Y. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. J Clin Exp Hematop. 2013;53(1):95–9.
Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H, et al. Successful treatment of TAFRO syndrome, a variant of multicentric Castleman’s disease, with cyclosporine A: possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med. 2015;236(4):289–95.
Man L, Goudar RK. Reversal of cardiomyopathy with tocilizumab in a case of HIV-negative Castleman’s disease. Eur J Haematol. 2013;91(3):273–6.
Kanda J, Kawabata H, Yamaji Y, Ichinohe T, Ishikawa T, Tamura T, et al. Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody. Int J Hematol. 2007;85(3):207–11.
Yamamoto S, Nakatani S, Kijima K, Kohno K, Morita S, Koito H, et al. Multicentric Castleman’s disease with reversible left ventricular diffuse hypokinesis. Nihon Naika Gakkai Zasshi. 2001;90(1):123–6.
Raj S, Franco VI, Lipshultz SE. Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. Curr Treat Options Cardiovasc Med. 2014;16(6):315.
Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217–24.
Kilickap S, Yavuz B, Aksoy S, Sahiner L, Dincer M, Harputluoglu H, et al. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin’s lymphoma. Med Oncol. 2008;25(4):437–42.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Yasuda, S., Tanaka, K., Ichikawa, A. et al. Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy. Int J Hematol 104, 512–518 (2016). https://doi.org/10.1007/s12185-016-2025-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-016-2025-z